In the first half of the year, the performance of the Chinese medicine sector was excellent, and the second half of the year continued to be optimistic

In the first half of the year, most companies in the Chinese medicine sector performed very well
.
According to statistics, 73 listed companies in the Chinese medicine sector achieved total operating income of 162.
2 billion yuan in the first half of 2021, an increase of 15.
12% over the same period last year; total net profit attributable to shareholders of listed companies was 24.
2 billion yuan, an increase from the same period last year 25.
05%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 17 billion yuan, an increase of 27.
56% over the same period last year
.
It is worth mentioning that many companies have net profits exceeding 1 billion yuan
.
The top companies in terms of net profit are: Baiyunshan 2.
502 billion yuan, Yunnan Baiyao 1.
802 billion yuan, China Resources 391.
365 billion yuan, Pien Tzehuang 1.
115 billion yuan, and Tasly 1.
02 billion yuan
.
The industry believes that the outstanding performance of the Chinese medicine sector in the first half of the year was mainly due to the fact that frequent favorable policies + consumption attributes + valuation advantages constitute industry opportunities
.
Among them, favorable policies are the main driving force for the continued development of the Chinese medicine sector
.
It is understood that as a great creation of the Chinese nation and a treasure of ancient Chinese science, traditional Chinese medicine has always been the key direction of the country's continuous support and development
.
In recent years, the pharmaceutical industry has continued to obtain favorable policies
.
Since the beginning of this year, from the country to the local level, a number of heavy boost policies have also been introduced
.
For example, in February of this year, the "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine" issued by the state further improved the top-level design
.
On June 30, the National Health Commission and the State Administration of Traditional Chinese Medicine jointly formulated the "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine", and also proposed to strengthen the Medical work
.
In addition, Hunan, Jiangsu, Beijing, Fuzhou, Taian, Yuxi, Linyi and other places have issued relevant documents in order to further promote the high-quality development of the Chinese medicine industry, and are promoting the inclusion of Chinese medicine and Chinese medicine in medical insurance.

.
For example, the "Several Policies for Medical Security Supporting the Development of Traditional Chinese Medicine" issued by Sichuan Province (hereinafter referred to as the "Policies"), from supporting the inclusion of Chinese medicine institutions into the designated medical insurance scope, supporting the inclusion of Chinese medicine service items into the medical insurance scope, and advancing the payment method of traditional Chinese medicine services and medical insurance A total of 15 dry goods in the four major aspects of reform and promotion of the price reform of Chinese medicine services have been clarified
.
The analysis believes that with the implementation of favorable policies for the Chinese medicine industry in the country and even localities, Chinese medicine companies will usher in a better development opportunity, and the performance of related pharmaceutical companies will continue to develop in the second half of the year
.
At the same time, the Chinese medicine sector will also be favored by more market investors in the short term
.
However, it should be noted that in recent years, the supervision of the Chinese medicine industry has become stricter, and the development of the industry has gradually become standardized and standardized.
Affected by this, the Chinese medicine industry will also enter a period of adjustment pains
.
In this context, the two main lines of innovation and consumption will be the long-term development direction of the Chinese medicine industry.
The industry’s suggestions can focus on: transformation of innovative Chinese medicine research and development, traditional Chinese medicine companies in the field of "medical insurance and immunity" general consumer goods, and low-cost, A supplier of high-quality Chinese herbal medicines
.